Hematological Malignancies Clinical Trial
Official title:
An Evaluation of the Effect of 'Open Window', an Art Intervention, on Psychological Well-being and Experience of Stem Cell Transplantation for the Treatment of Haematological Malignancies
Verified date | June 2012 |
Source | St. James's Hospital, Ireland |
Contact | n/a |
Is FDA regulated | No |
Health authority | Ireland: Medical Ethics Research Committee |
Study type | Interventional |
The 'Open Window' Study is a prospective longitudinal study using a 4 group randomised
control trial design to evaluate the psychological effect of 'Open Window' on the
consequences of long term isolation on patients undergoing stem cell transplantation
treatment of haematological malignancies. This study uses a randomised control trial design,
which is widely used in healthcare settings to test the effects of interventions and testing
cause and effect relationships between variables. A mixed methods approach for data
collection and data analysis is being used. This will facilitate measurement of patients'
psychological response to 'Open Window' using questionnaires and exploration of subjective
feelings in relation to personal experiences of having a stem cell transplant through semi
structured interviews.
Hypothesis to be tested
'Open Window' has no effect on patients' levels of anxiety, depression, or distress when
undergoing a stem cell transplant.
Results:
Of the 199 patients in the study, 96 were randomized to the intervention group and 103 to
the control group. Participants in the intervention group had significantly reduced levels
of anxiety on the day before transplant (P = 0.001), at day 7 (P = 0.041), and day 60 (P =
0.035). There was a significant reduction in depression before transplant (P= 0.022).
Participants in the intervention group reported better experiences (P < 0.005).
Status | Completed |
Enrollment | 198 |
Est. completion date | January 2010 |
Est. primary completion date | January 2010 |
Accepts healthy volunteers | No |
Gender | Both |
Age group | 16 Years and older |
Eligibility |
Inclusion Criteria: Patients admitted to the Denis Burkitt unit for an autologous or allogeneic stem cell transplant. Patients who gives informed consent to participate in the study Patients who can read and speak English reasonably well. Patients who do not have communication difficulties, intellectual disabilities or known mental illness Patients who will be treated as an in-patient in the Denis Burkitt Unit following transplantation. Exclusion Criteria: Patients who are not undergoing a stem cell transplant Patients who do not consent to participate in the study Patients with communication difficulties, learning disabilities, mental illness, prisoners, young offenders. Patients who are transferred to other units immediately following transplantation |
Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Supportive Care
Country | Name | City | State |
---|---|---|---|
Ireland | St. James's Hospital | Dublin |
Lead Sponsor | Collaborator |
---|---|
St. James's Hospital, Ireland | Irish Cancer Society |
Ireland,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | The primary outcome measures are Anxiety, Depression and Distress. Measures will be taken on 7 occasions over a six month period. | Six Months | No | |
Secondary | Patient expectations in relation to the experience of having a stem cell transplant. | Day + 30 | No |
Status | Clinical Trial | Phase | |
---|---|---|---|
Terminated |
NCT03248479 -
Magrolimab Monotherapy or Magrolimab in Combination With Azacitidine in Participants With Hematological Malignancies
|
Phase 1 | |
Recruiting |
NCT05454241 -
CD7 CAR-T for Patients With r/r CD7+ Hematologic Malignancies
|
Phase 2 | |
Recruiting |
NCT06041815 -
Correlation Between Gut Microbiota and Clinical Response to CAR-T Treatment for Hematological Malignancies
|
||
Active, not recruiting |
NCT05005442 -
A Study of Pembrolizumab/Vibostolimab (MK-7684A) in Relapsed/Refractory Hematological Malignancies (MK-7684A-004, KEYVIBE-004)
|
Phase 2 | |
Recruiting |
NCT02300571 -
Observational Study of the Combination of Post-transplant High Dose Cyclophosphamide, Tacrolimus and Mycophenolate Mofetil for the Prevention of Acute Graft-versus-Host Disease in Patients Eligible to Allogeneic Hematopoietic Stem Cell Transplant
|
N/A | |
Active, not recruiting |
NCT01428973 -
Minitransplants With HLA-matched Donors : Comparison Between 2 GVHD Prophylaxis Regimens
|
Phase 2 | |
Terminated |
NCT00506948 -
Thymoglobulin, Sirolimus and Mycophenolate Mofetil for Prevention of Acute Graft-Versus-Host Disease (GVHD)
|
Phase 2 | |
Completed |
NCT01162096 -
Reduced Intensity Haploidentical Transplant for Hematological Malignancies
|
Phase 1/Phase 2 | |
Completed |
NCT00379587 -
Rituximab for Prevention of Chronic GVHD
|
Phase 1/Phase 2 | |
Active, not recruiting |
NCT04557098 -
A Study of Teclistamab in Participants With Relapsed or Refractory Multiple Myeloma
|
Phase 2 | |
Recruiting |
NCT04283097 -
Safety, Tolerability and Pharmacokinetics Study of KPG-818 in Hematological Malignancies Subjects
|
Phase 1 | |
Completed |
NCT03067155 -
CMV Specific T Cell Therapy After Allogeneic Stem Cell Transplantation.
|
Phase 2 | |
Completed |
NCT01725555 -
A Study to Assess the Effect of Food on the Bioavailability of the IGF-1R Inhibitor AXL1717 in Patients With Advanced Malignant Tumors
|
Phase 1 | |
Completed |
NCT00438178 -
Safety and Efficacy of Obatoclax Mesylate (GX15-070MS) for the Treatment of Hematological Malignancies
|
Phase 1 | |
Completed |
NCT03711604 -
Compassionate Use Study of Tenalisib (RP6530)
|
Phase 1/Phase 2 | |
Withdrawn |
NCT01168882 -
Safety and Tolerability of RGB-286638 in Patients With Selected, Relapsed or Refractory Hematological Malignancies
|
Phase 1 | |
Completed |
NCT01246206 -
Tacrolimus and Thymoglobulin, as GvHD Prophylaxis in Patients Undergoing Related Donor HCT
|
Phase 2 | |
Completed |
NCT01172132 -
The Use of Intensive Care in Critically Ill Cancer Haematological Patients: "TRIAL-OH"
|
N/A | |
Completed |
NCT00506402 -
A Phase 1 Study of MKC-1 in Patients With Refractory Hematologic Malignancies
|
Phase 1 | |
Active, not recruiting |
NCT00163644 -
RCT to Investigate Whether an Exercise Programme Improves the Physical Performance and QOL After BMT
|
N/A |